Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552058 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
NCT00552058 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 439 participants.
The verdict
NCT00552058, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Interventions
- OTHER Placebo
- BIOLOGICAL certolizumab pegol (CDP870, CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552058
The ClinicalTrials.gov registry entry for NCT00552058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00552058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00552058 about?
NCT00552058 is a clinical study titled "Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease". The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
What is the current status of trial NCT00552058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2008-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00552058?
The interventions under investigation include: Placebo (OTHER), certolizumab pegol (CDP870, CZP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00552058?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.